HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment

25 May 2020

The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.

Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment
The research team led by Professor Ken Yung Kin-lam (right), Professor of the Department of Biology, and Dr Jeffery Huang Zhifeng, Associate Professor of the Department of Physics at HKBU, has developed a pioneering nanomatrix that can stimulate neural stem cells to differentiate into nerve cells and can offer help for treating Parkinson's disease.

They found that the transplantation of these nerve cells into rats with Parkinson's disease progressively improved their symptoms, with the new cells replacing damaged nerve cells around the transplantation site. This novel invention provides promising insights into stem cell therapies and offers hope of a new treatment for Parkinson's disease.

Although current treatments cannot cure Parkinson's disease completely, stem cell therapy a promising potential treatment. It involves cultivating stem cells for differentiation into new and healthy cells, tissues or organs which can then be transplanted to human body to replace damaged or dead cells.

Conventional stem cell culturing techniques require a large number of additional growth factors in a culture medium. The chemicals used may stimulate the growth of cancer cells and increase the risk of developing tumours after transplantation to human body. Furthermore, the brain‐like structures obtained from this method usually poorly resemble their counterparts in the brain. Efficiency of the conventional culturing techniques is low as the process spans more than a month, resulting in a high risk of contamination.

The pioneering nanomatrix, developed by a research team led by Professor Ken Yung Kin-lam, Professor of the Department of Biology and Dr Jeffery Huang Zhifeng, Associate Professor of the Department of Physics at HKBU, can induce the rapid and specific differentiation of neural stem cells into miniature substantia nigra-like structures (mini-SNLSs). These mini-SNLSs mainly comprise dopaminergic neurons and they can replace the damaged or degenerated cells in the substantia nigra in the brain.

The nanomatrix consists of a silica plate coated with a nanostructure layer. Thickness of the nanomatrix is only 550–730 nm, yet there are trillions of nanozigzag structures on the surface which can initiate the growth of neural stem cells into mini-SNLSs without the use of chemical growth factors.

"When the neural stem cells come into physical contact with our tailor-made nanozigzag matrix in vitro, the 'physical massage' can induce the cells to differentiate rapidly into the desired dopaminergic neurons. A self-organised mini-brain-like structure can be developed in only 2 weeks with risk of carcinogenesis substantially reduced," said Dr Huang.

According to Professor Yung, the technology "lays the foundation for research into stem cell therapies that may ultimately cure Parkinson's disease." He also believes the invention has shown great potential for the treatment of other incurable diseases, such as Alzheimer's disease and certain types of cancer.

Related news

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment

7 Jul 2020

The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.

Read more 
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail

7 Jul 2020

The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
Piramal acquires solid oral dosage drug product facility from G&W Laboratories

Piramal acquires solid oral dosage drug product facility from G&W Laboratories

22 Jun 2020

The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.

Read more 
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment

22 Jun 2020

The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.

Read more 
Sanofi to build EUR 490 million vaccine production facility in France

Sanofi to build EUR 490 million vaccine production facility in France

16 Jun 2020

The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccines

Read more 
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's

8 Jun 2020

Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.

Read more 
Emergent bags $628 million landmark CDMO deal to produce COVID-19 vaccine candidates

Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates

2 Jun 2020

The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.

Read more 
Changes needed to prevent controversial pay-for-delay pharma deals

Changes needed to prevent controversial pay-for-delay pharma deals

26 May 2020

Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.

Read more 
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient

26 May 2020

SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.

Read more